RAPT Therapeutics, Inc. (RAPT) Total Current Liabilities (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Total Current Liabilities for 5 consecutive years, with $10.4 million as the latest value for Q3 2024.
- Quarterly Total Current Liabilities fell 52.57% to $10.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Sep 2024, down 52.57% year-over-year, with the annual reading at $21.8 million for FY2023, 53.52% up from the prior year.
- Total Current Liabilities hit $10.4 million in Q3 2024 for RAPT Therapeutics, down from $14.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $21.8 million in Q3 2023 to a low of $9.6 million in Q4 2021.
- Historically, Total Current Liabilities has averaged $14.6 million across 5 years, with a median of $13.4 million in 2020.
- Biggest five-year swings in Total Current Liabilities: soared 74.82% in 2023 and later tumbled 52.57% in 2024.
- Year by year, Total Current Liabilities stood at $11.7 million in 2020, then decreased by 18.28% to $9.6 million in 2021, then skyrocketed by 48.24% to $14.2 million in 2022, then soared by 53.52% to $21.8 million in 2023, then crashed by 52.55% to $10.4 million in 2024.
- Business Quant data shows Total Current Liabilities for RAPT at $10.4 million in Q3 2024, $14.8 million in Q2 2024, and $21.2 million in Q1 2024.